U.S. DEPARTM COMMERCE PATENT AND TRADEMARK OFFICE REV 11-2000) **046US** RDIDe TRANSMITTAL LETTER TO THE UNITED STATES U.S. APPLICATION NO. (IF KNOWN, SEE 37 CFR DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371 INTERNATIONAL APPLICATION NO. INTERNATIONAL FILING DATE PRIORITY DATE CLAIMED TITLE OF INVENTION METHOD FOR PREPARING ENDOTOXIN-FREE NUCLEIC ACIDS OR NUCLEIC ACIDS WITH REDUCED ENDOTOXIN CONTENT AND THE USE THEREOF APPLICANT(S) FOR DO/EO/US GRIMM, Stefan; and NEUDECKER, Frank Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information: This is a FIRST submission of items concerning a filing under 35 U.S.C. 371. This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371. \boxtimes This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include itens (5), (6), (9) and (24) indicated below. The US has been elected by the expiration of 19 months from the priority date (Article 31). 5. A copy of the International Application as filed (35 U.S.C. 371 (c) (2)) is attached hereto (required only if not communicated by the International Bureau). b. □ has been communicated by the International Bureau. c. 🗆 is not required, as the application was filed in the United States Receiving Office (RO/US). An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)). a. 🖾 is attached hereto. has been previously submitted under 35 U.S.C. 154(d)(4). b. 🗆 Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371 (c)(3)) are attached hereto (required only if not communicated by the International Bureau). b. □ have been communicated by the International Bureau. have not been made; however, the time limit for making such amendments has NOT expired. have not been made and will not be made. An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)). 9. \boxtimes An oath or declaration of the inventor(s) (35 U.S.C. 371 (c)(4)). 10. An English language translation of the annexes of the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371 (c)(5)). \boxtimes 11. A copy of the International Preliminary Examination Report (PCT/IPEA/409). 12. \boxtimes A copy of the International Search Report (PCT/ISA/210). Items 13 to 20 below concern document(s) or information included: 13. An Information Disclosure Statement under 37 CFR 1.97 and 1.98. 14. An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included. \boxtimes 15. A FIRST preliminary amendment. 16. A SECOND or SUBSEQUENT preliminary amendment. 17. A substitute specification. 18. A change of power of attorney and/or address letter.

A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 35 U.S.C. 1.821 - 1.825.

A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4).

General Appointment of Representative for U.S. Patent and Trademark Office Matters; and

A second copy of the published international application under 35 U.S.C. 154(d)(4).

19.

20.

21.

22. 23. \boxtimes

Certificate of Mailing by Express Mail

Other items or information:

Return postcard.

PCTUS1/REV03

	TION NO. (IF KNOWN, SEE 3 INTERNATIONAL APPLICATION NO.				ATTORNEY'S DOCKET NUMBER RDID01046US						
24. The following fees are submitted:.						CALCULATIONS PTO USE ONLY					
BASIC NATIONAL FEE (37 CFR 1.492 (a) (1) - (5)): Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO							_				
✓ International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO											
☐ International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO											
☐ International preliminary examination fee (37 CFR 1.482) paid to USPTO but all claims did not satisfy provisions of PCT Article 33(1)-(4)											
International preliminary examination fee (37 CFR 1.482) paid to USPTO and all claims satisfied provisions of PCT Article 33(1)-(4)											
ENTER APPROPRIATE BASIC FEE AMOUNT =							\$860.00				
months from the ea	00 for furnishing the oath or declar priest claimed priority date (37 CI	FR 1.492 (e)).	20				\$0.00	<u></u>			
CLAIMS	NUMBER FILED	NUMBER EXTR	A	RATE			60.00				
Total claims	- 20 = - 3 =	0		x \$18.00 x \$80.00			\$0.00 \$0.00				
Independent claims - 3 = Multiple Dependent Claims (check if applicable).		0 X 360.0					\$0.00				
TOTAL OF ABOVE CALCULATIONS =					=		\$860.00				
Applicant claims small entity status. (See 37 CFR 1.27). The fees indicated above are reduced by 1/2.							\$0.00				
Applicant claims small entity status. (See 37 CFR 1.27). The fees indicated above are reduced by 1/2. SUBTOTAL =					=		\$860.00				
Processing fee of \$130.00 for furnishing the English translation later than 20 30 months from the earliest claimed priority date (37 CFR 1.492 (f)).							\$0.00				
TOTAL NATIONAL FEE =						\$860.00					
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31) (check if applicable).							\$0.00				
TOTAL FEES ENCLOSED =				=		\$860.00					
·							unt to be: efunded	\$			
							charged	\$			
a.	heck in the amount of	to cover the ab	ove fees	s is enclosed.							
	Please charge my Deposit Account No. 50-0877 in the amount of \$860.00 to cover the above fees. A duplicate copy of this sheet is enclosed.										
	The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 50-0877. A duplicate copy of this sheet is enclosed.										
	appropriate time limit under 37 ust be filed and granted to restor				etitio	n to r	evive (37 CFF	t			
	ESPONDENCE TO:	e the application to per	iumg st	1/		n /	1/1				
Kenneth J. Waite			SIGNATURE								
Roche Diagnostics Corporation			/								
9115 Hague Road, Bldg. D P.O. Box 50457			Kenneth J. Waite								
Indianapolis, IN 46250-0457			NAME								
Telephone No.: (317) 521-3104 Facsimile No.: (317) 521-2883				45,189							
Facsimile No.: (317) 521-2883			REGISTRATIO				N NUMBER				
		July 26, 2	001								
						DATE					